Monk Terri G
Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA.
Crit Care. 2004;8 Suppl 2(Suppl 2):S45-8. doi: 10.1186/cc2824. Epub 2004 Jun 14.
Preoperative anemia in a surgical patient predisposes to poor outcomes and allogeneic blood transfusions. As an alternative to transfusions, pharmacologic management of preoperative anemia with recombinant human erythropoietin (rHuEPO) has been well studied in many different types of surgery. rHuEPO, when used alone or in combination with preoperative autologous blood donation before elective surgery, stimulates erythropoiesis and helps to avoid or reduce the need for allogeneic blood transfusions. The clinical evidence on preoperative use of rHuEPO in orthopedic, cardiac, and cancer surgery, as well as in bloodless surgery, is reviewed.
外科手术患者术前贫血易导致不良预后及异体输血。作为输血的替代方法,重组人促红细胞生成素(rHuEPO)对术前贫血的药物治疗已在多种不同类型手术中得到充分研究。rHuEPO单独使用或与择期手术前的术前自体献血联合使用时,可刺激红细胞生成,并有助于避免或减少异体输血的需求。本文综述了rHuEPO在骨科、心脏、癌症手术以及非输血手术中术前使用的临床证据。